BTX Brooklyn Immunotherapeutics Inc

$16.10 $0.00 (0.00%)
Overall

BTX Stock Analysis Overview

What this means: Brooklyn Immunotherapeutics Inc (BTX) gets a very poor rank from InvestorsObserver. Our comprehensive analysis of fundamental and technical factors gives BTX a rank of 8. Our methodology considers analysis of the company's financial situation and how it has traded recently. BTX rank of 8 means that it ranks below 92% of stocks.

Who this matters to: Overall Ranking is a comprehensive evaluation. It considers technical and fundamental factors and is a good starting point for evaluating a stock.

View Sample Report
Fundamental PREMIUM

BTX Fundamental Analysis

Who this matters to: The Fundamental Ranking considers the health of the underlying company. It is best used by longer-term buy-and-hold investors.

Upgrade to Premium to unlock Fundamental Ranking

Short-Term Technical PREMIUM

BTX Short-Term Technical Analysis

Who this matters to: The Short-Term Technical Ranking evaluates a stock’s trading over the past month. This is most useful for short- to medium-term stock and option traders.

Upgrade to Premium to unlock Short-Term Technical Ranking

Long-Term Technical PREMIUM

BTX Long-Term Technical Analysis

Who this matters to: The Long-Term Technical Ranking is a good gauge of how a stock has traded over the past several months. This is useful for medium to long-term stock and option traders.

Upgrade to Premium to unlock Long-Term Technical Ranking

Analyst Ranking PREMIUM

BTX Analyst Ranking

Who this matters to: Analyst Ranking shows you which stocks Wall Street analysts like the most. Since analysts build valuation models, this is most useful for medium to long-term investors who are interested in a valuation-based approach.

Upgrade to Premium to unlock Analyst Ranking Analysis

Valuation PREMIUM

BTX Valuation Ranking Analysis

Who this matters to: Valuation Ranking is most-useful for value-focused investors who plan to hold a stock for the long term.

Upgrade to Premium to unlock Valuation Ranking

Stock Sentiment PREMIUM

BTX Stock Sentiment Analysis

Who this matters to: Sentiment Rank looks at the past five trading days. This is our shortest-term evaluation and is best used by people with a very short horizon.

Upgrade to Premium to unlock Stock Sentiment Ranking

BTX Stock Analysis Overview

What this means: Brooklyn Immunotherapeutics Inc (BTX) gets a very poor rank from InvestorsObserver. Our comprehensive analysis of fundamental and technical factors gives BTX a rank of 8. Our methodology considers analysis of the company's financial situation and how it has traded recently. BTX rank of 8 means that it ranks below 92% of stocks.

Who this matters to: Overall Ranking is a comprehensive evaluation. It considers technical and fundamental factors and is a good starting point for evaluating a stock.

Create a FREE account to see full AMZN report

BTX Fundamental Analysis

Who this matters to: The Fundamental Ranking considers the health of the underlying company. It is best used by longer-term buy-and-hold investors.

Upgrade to Premium to unlock Fundamental Ranking

BTX Short-Term Technical Analysis

Who this matters to: The Short-Term Technical Ranking evaluates a stock’s trading over the past month. This is most useful for short- to medium-term stock and option traders.

Upgrade to Premium to unlock Short-Term Technical Ranking

BTX Long-Term Technical Analysis

Who this matters to: The Long-Term Technical Ranking is a good gauge of how a stock has traded over the past several months. This is useful for medium to long-term stock and option traders.

Upgrade to Premium to unlock Long-Term Technical Ranking

BTX Analyst Ranking

Who this matters to: Analyst Ranking shows you which stocks Wall Street analysts like the most. Since analysts build valuation models, this is most useful for medium to long-term investors who are interested in a valuation-based approach.

Upgrade to Premium to unlock Analyst Ranking Analysis

BTX Valuation Ranking Analysis

Who this matters to: Valuation Ranking is most-useful for value-focused investors who plan to hold a stock for the long term.

Upgrade to Premium to unlock Valuation Ranking

BTX Stock Sentiment Analysis

Who this matters to: Sentiment Rank looks at the past five trading days. This is our shortest-term evaluation and is best used by people with a very short horizon.

Upgrade to Premium to unlock Stock Sentiment Ranking

Brooklyn Immunotherapeutics Inc (BTX) Analyst Forecast

  • Last Price $16.10
  • Previous Close $16.10
  • Change $0.00
  • Open $16.00
  • Volume 2,833,300
  • Avg. Volume (100-day) 0
  • Market Cap 687,223,316
  • Days Range 15.09 - 16.3
  • 52-week Range 3.59 - 80.67
  • Dividend Yield
  • Ex. Dividend Date
  • P-E
  • EPS
  • Earnings Date 09/20/21
  • Sector Healthcare
  • Industry Biotechnology
  • Avg. Analyst Rec. Premium
  • Beta 1.570
  • PEG Ratio
Brooklyn ImmunoTherapeutics Inc is a clinical stage biopharmaceutical company. It is developing IRX-2, a novel hd-IL-2 -based therapy, to treat patients with cancer. IRX-2 delivers hd-IL-2 and other key cytokines to potentially restore immune function in the tumor microenvironment, enabling the immune system to attack cancer cells.

My Watchlists

Follow Your Favorite Stocks